MetaCap

Krystal Biotech (KRYS) vs Neurocrine Biosciences (NBIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Krystal Biotech (KRYS) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 45.7% versus a gain of 6.2%. Over five years, KRYS leads with a +675.9% price change compared with +73.1% for NBIX. Neurocrine Biosciences is the larger company by market cap ($15.24 billion vs $9.15 billion), about 1.7 times the size, while Krystal Biotech is growing revenue faster (+33.9% vs +21.4%).

On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.2x vs 33.5x for Krystal Biotech). Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus 16.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KRYS+45.69%NBIX+6.16%
+83%+33%-18%
Nov 21, 20251 yearNov 20, 2026
KRYS+489.82%NBIX+75.04%
+648%+296%-56%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KRYS versus NBIX key metrics
MetricKRYSNBIX
Share price$308.89$150.57
Market cap$9.15B$15.24B
1-day change-2.19%-3.84%
YTD return+25.29%+6.16%
1-year return+45.69%+6.16%
5-year return+675.91%+73.11%
P/E ratio (TTM)41.9722.34
Forward P/E33.4712.24
EPS (TTM)$7.36$6.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$389.13M$2.86B
Revenue growth (YoY)+33.94%+21.45%
Net income (latest FY)$204.83M$478.60M
Gross margin—98.18%
Operating margin41.45%21.64%
Net margin52.64%16.73%
52-week high$382.54$186.12
52-week low$212.02$122.14
Distance from 52-week high-19.25%-19.10%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+25.68%+38.50%
Average volume283.88K1.34M
Shares outstanding29.63M101.22M
Employees2952,500
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRYS has outperformed NBIX by 39.5 percentage points over the past year.
  • Krystal Biotech trades at a higher earnings multiple (42.0x vs 22.3x trailing P/E).
  • Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus 16.7 cents for Neurocrine Biosciences.
  • Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs +21.45%).

About Krystal Biotech

KRYS stock →

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees

About Neurocrine Biosciences

NBIX stock →

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees

KRYS vs NBIX FAQ

Which is bigger, Krystal Biotech or Neurocrine Biosciences?

Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $15.24B compared with $9.15B for Krystal Biotech (KRYS).

Which stock has performed better over the past year, KRYS or NBIX?

KRYS returned +45.69% over the past 12 months, compared with +6.16% for NBIX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, KRYS or NBIX?

NBIX has the lower trailing P/E at 22.3, versus 42.0 for KRYS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Krystal Biotech and Neurocrine Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons